3 Papers
Tao Yin is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Apatinib & Medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Baocai Xing,Yilei Mao,Gao-Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan +39 more
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
767
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Jian-Ming Xu,Jie Shen,Shanzhi Gu,Yun Zhang,Lihua Wu,Jian Wu,Guoliang Shao,Yanqiao Zhang,Li Xu,Tao Yin,Jingfeng Liu,Zhenggang Ren,Jianping Xiong,Xianhai Mao,L Zhang,Jiayin Yang,Le-Qun Li,Xiaoming Chen,Zhiming Wang,Kangsheng Gu,Xi Chen,Zhanyu Pan,Kuansheng Ma,Xinmin Zhou,Zujiang Yu,Enxiao Li,Guowen Yin,Xiao Zhang,Shuni Wang,Quan Ren Wang +29 more
TL;DR: Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting, and might represent a novel treatment option for these patients.
484
Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).
Yun Zhang,Jianming Xu,Jie Shen,Shanzhi Gu,Lihua Wu,Jian Wu,Guoliang Shao,Yanqiao Zhang,Li Xu,Tao Yin,Jingfeng Liu,Zhenggang Ren,Jianping Xiong,Xianhai Mao,L Zhang,Jiayin Yang,Le-Qun Li,Xiaoming Chen,Zhiming Wang,Quanren Wang +19 more
TL;DR: Long-term follow-up of C+A demonstrated remarkable survival benefit in advanced HCC pts, which further suggested that C-A is a promising combination therapy in advancedHCC pts.